FibroGen (FGEN) 10-Q2022 Q3 Quarterly report

Filed: 7 Nov 22, 4:12pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accessible, ambulant, CDK, cured, dedication, default, delandistrogene, draft, flexibility, foreclosure, fundraising, incomplete, inquiry, insolvency, Italfarmaco, length, moxeparvovec, ninety, NovaQuest, outpace, partnership, penalize, prepay, prepayment, refund, relinquish, RIFA, stipulation, summary, waived, Yen

Removed: alleging, band, basket, CIA, finalized, linked, managed, narrow, phased, reverse, safely, shown, stabilize, WHITNEY

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated FGEN transcripts

FGEN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Enrique Conterno, Chief Executive Officer of FibroGen, Inc. (the "Company”), and Juan Graham, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2022, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 7, 2022

In Witness Whereof, the undersigned have set their hands hereto as of the 7th day of November, 2022.


/s/ Enrique Conterno		/s/ Juan Graham
Enrique Conterno		Juan Graham
Chief Executive Officer		Senior Vice President and Chief Financial Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of FibroGen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.